{"title":"A92","authors":"M. Mukhacheva, B. Beyn","doi":"10.1016/j.ejcsup.2015.08.068","DOIUrl":null,"url":null,"abstract":"<div><p>This work is devoted to the actual problem of studying modern ideas about the systemic treatment of brain tumors, in particular on the implementation and effectiveness of modern methods of immunomodulation in neuro-oncology. The aim is to clarify the existence of patients with brain tumors immunosuppression, resulting in testimony to the development and application of methods of immunotherapy. Method of research consistent with the goal and objectives of the study, which included a dynamic examination of 32 operated patients with hemispheric brain gliomas. Cycloferon interferonogens from the group, which has antiviral and antitumor action potential was used as an immunomodulator us. It is of interest to determine the effectiveness of immunomodulatory action of cycloferon in patients with brain tumors in different phases of development of cancer. This work represents a scientific novelty and practical significance for solving urgent problems of neurology and neurosurgery – the study of the cycloferon drug, has proved its effectiveness in the reinforcement of clinical remission and increased the life expectancy of patients with brain tumors after surgery.</p></div>","PeriodicalId":11675,"journal":{"name":"Ejc Supplements","volume":"13 1","pages":"Pages 38-39"},"PeriodicalIF":0.0000,"publicationDate":"2015-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.ejcsup.2015.08.068","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Ejc Supplements","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1359634915000695","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 0
Abstract
This work is devoted to the actual problem of studying modern ideas about the systemic treatment of brain tumors, in particular on the implementation and effectiveness of modern methods of immunomodulation in neuro-oncology. The aim is to clarify the existence of patients with brain tumors immunosuppression, resulting in testimony to the development and application of methods of immunotherapy. Method of research consistent with the goal and objectives of the study, which included a dynamic examination of 32 operated patients with hemispheric brain gliomas. Cycloferon interferonogens from the group, which has antiviral and antitumor action potential was used as an immunomodulator us. It is of interest to determine the effectiveness of immunomodulatory action of cycloferon in patients with brain tumors in different phases of development of cancer. This work represents a scientific novelty and practical significance for solving urgent problems of neurology and neurosurgery – the study of the cycloferon drug, has proved its effectiveness in the reinforcement of clinical remission and increased the life expectancy of patients with brain tumors after surgery.
期刊介绍:
EJC Supplements is an open access companion journal to the European Journal of Cancer. As an open access journal, all published articles are subject to an Article Publication Fee. Immediately upon publication, all articles in EJC Supplements are made openly available through the journal''s websites.
EJC Supplements will consider for publication the proceedings of scientific symposia, commissioned thematic issues, and collections of invited articles on preclinical and basic cancer research, translational oncology, clinical oncology and cancer epidemiology and prevention.
Authors considering the publication of a supplement in EJC Supplements are requested to contact the Editorial Office of the EJC to discuss their proposal with the Editor-in-Chief.
EJC Supplements is an official journal of the European Organisation for Research and Treatment of Cancer (EORTC), the European CanCer Organisation (ECCO) and the European Society of Mastology (EUSOMA).